"PHILADELPHIA, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American:HEB) announced today its financial results for the third quarter ended September 30, 2017."
"We have secured our first country approval for Ampligen® in ME/CFS and we expect several more in the coming years."...